- 1 Introduced by Committee on Health and Welfare
- 2 Date:

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

- 3 Subject: Health; health care reform; pharmacy benefit managers; hospitals;
- 4 Green Mountain Care Board
 - Statement of purpose of bill as introduced: This bill proposes to establish specific parameters by which pharmacy benefit managers would set the maximum allowable cost for prescription drug reimbursement. It would require hospitals to provide notice to individuals placed in observation status and to alert individuals receiving observation services about the potential financial implications. It would also direct the Department of Vermont Health Access to adopt a prospective payment system for home health agencies. The bill would reinstate the Health Care Oversight Committee permanently and the Mental Health Oversight Committee for one year and it would establish a long-term care evaluation task force to assess and catalogue in-home, long-term care programs operated or subsidized by the State. The bill would require updates on the Vermont Health Care Innovation Project and direct the Agency of Human Services to identify overlap and duplication in the delivery of services. It would also modify the circumstances under which the

a children's product containing a chemical of high concern to children.

2	An act relating to pharmacy benefit managers, hospital observation status, and chemicals of high concern to children
3	It is hereby enacted by the General Assembly of the State of Vermont:
4	* * * Pharmacy Benefit Managers * * *
5	Sec. 1. 18 V.S.A. chapter 79 is amended to read:
6	CHAPTER 79. PHARMACY AUDITS BENEFIT MANAGERS
7	Subchapter 1. General
8	§ 3801. DEFINITIONS
9	As used in this subchapter chapter:
10	(1)(A) "Health insurer" shall have the same meaning as in section
11	9402 of this title and shall include:
12	(i) a health insurance company, a nonprofit hospital and
13	medical service corporation, and health maintenance organizations;
14	(ii) an employer, a labor union, or another group of persons
15	organized in Vermont that provides a health plan to beneficiaries who are
16	employed or reside in Vermont; and
17	(iii) except as otherwise provided in section 3805 of this title,
18	the State of Vermont and any agent or instrumentality of the State that
19	offers, administers, or provides financial support to State government.
20	(B) The term "health insurer" shall not include Medicaid or any
21	other Vermont public health care assistance program.

1	(2) "Health plan" means a health benefit plan offered, administered,
2	or issued by a health insurer doing business in Vermont.
3	(3) "Maximum allowable cost" means the per unit drug product
4	reimbursement amount, excluding dispensing fees, for a group of
5	therapeutically and pharmaceutically equivalent multisource generic
6	drugs.
7	(4) "Pharmacy" means any individual or entity licensed or
8	registered under 26 V.S.A. chapter 36.
9	(4)(5) "Pharmacy benefit management" means an arrangement for
10	the procurement of prescription drugs at a negotiated rate for
11	dispensation within this State to beneficiaries, the administration or
12	management of prescription drug benefits provided by a health plan for
13	the benefit of beneficiaries, or any of the following services provided with
14	regard to the administration of pharmacy benefits:
15	(A) mail service pharmacy;
16	(B) claims processing, retail network management, and payment
17	of claims to pharmacies for prescription drugs dispensed to beneficiaries;
18	(C) clinical formulary development and management services;
19	(D) rebate contracting and administration;
20	(E) certain patient compliance, therapeutic intervention, and
21	generic substitution programs; and

1	(F) disease or chronic care management programs.
2	(5)(6) "Pharmacy benefit manager" means an entity that performs
3	pharmacy benefit management. The term includes a person or entity in a
4	contractual or employment relationship with an entity performing
5	pharmacy benefit management for a health plan.
6	(7) "Price index" means any variable, including average wholesale
7	price, wholesale acquisition cost, or average manufacturer's price, used by
8	a pharmacy benefit manager in determining drug product
9	reimbursement.
10	(6)(8) "Responsible party" means the entity, including a health
11	insurer or pharmacy benefit manager, responsible for payment of claims
12	for health care services other than:
13	(A) the individual to whom the health care services were
14	rendered;
15	(B) that individual's guardian or legal representative; or
16	(C) the agency of human services <u>Agency of Human Services</u> , its
17	agents, and contractors.
18	Subchapter 2. Pharmacy Audits
19	§ 3802. PHARMACY RIGHTS DURING AN AUDIT
20	* * *
21	Subchapter 3. Maximum Allowable Cost

1	§ 3811. CONTRACT PROVISIONS
2	Each contract between a pharmacy benefit manager and a contracted
3	pharmacy shall include:
4	(1) the sources used by the pharmacy benefit manager to calculate
5	the drug product reimbursement rate paid for all covered drugs available
6	under the pharmacy health benefit plan administered by the pharmacy
7	benefit manager;
8	(2) the price index methodology used to establish the drug product
9	reimbursement rate; and
10	(3) the process to appeal, investigate, and resolve disputes regarding
11	the drug product reimbursement rate.
12	§ 3812. MAXIMUM ALLOWABLE COST
13	For each drug for which a pharmacy benefit manager establishes a
14	maximum allowable cost in order to determine the reimbursement rate,
15	the pharmacy benefit manager shall do all of the following:
16	(1) Ensure that the drug is available nationwide from at least three
17	manufacturers of Food and Drug Administration Orange Book "AB"
18	rated equivalent multisource drugs.
19	(2) Ensure that maximum allowable cost applies only when a drug is
20	available for purchase without limitations by all pharmacists in the State

1	from licensed national or regional wholesalers, and that it will not apply if
2	the drug is unavailable for a period of 14 calendar days or more.
3	(3) Make available, in a format that is readily accessible and
4	understandable by a pharmacist, a list of the drugs subject to maximum
5	allowable cost, the actual maximum allowable cost for each drug, and the
6	source used to determine the maximum allowable cost.
7	(4) Update the maximum allowable cost list at least once every seven
8	<u>calendar days.</u>
9	(5) Establish or maintain a reasonable process for an administrative
10	appeals procedure to allow a dispensing pharmacy provider to contest a
11	listed maximum allowable cost as:
12	(A) not meeting the requirements of this section; or
13	(B) being below the cost at which the pharmacy obtained or may
14	obtain the drug.
15	(6)(A) Respond in writing to any appealing pharmacy provider as to
16	the merits of the dispute within seven calendar days after receipt of an
17	appeal. If, upon appeal, the pharmacy benefit manager finds in favor of
18	the appealing pharmacy, the pharmacy benefit manager shall adjust the
19	maximum allowable cost to no less than the actual acquisition cost
20	retroactive to the dispensing date of the original claim and make
21	adjustments to all similar claims in all pharmacies in the pharmacy

I	benefit manager's network. It, upon appeal, the pharmacy benefit
2	manager finds against the appealing pharmacy, the pharmacy benefit
3	manager shall provide the appealing pharmacy with the National Drug
4	Code of an alternative product on the maximum allowable cost list that is
5	available for purchase without limitations.
6	(B) If an appealing pharmacy can prove that its actual
7	acquisition cost exceeded the pharmacy benefit manager's maximum
8	allowable cost, the pharmacy benefit manager shall adjust the maximum
9	allowable cost to no less than the actual acquisition cost retroactive to the
10	dispensing date of the original claim. If no maximum allowable cost is
11	available for a drug, the pharmacy benefit manager shall reimburse the
12	pharmacy no less than the proven actual acquisition cost.
13	Subchapter 4. Benefit Administration
14	§ 3821. CHOICE OF PHARMACY
15	(a) A health insurer or pharmacy benefit manager shall permit a plan
16	beneficiary to fill a prescription at the pharmacy of his or her choice and
17	shall not impose differential cost-sharing requirements based on the
18	choice of pharmacy or otherwise promote the use of one pharmacy over
19	another.
20	(b) A health insurer or pharmacy benefit manager shall not condition
21	the reimbursement for dispensing prescription drugs in any way based on

1	whether a pharmacy or pharmacist participates in the health insurer's or
2	pharmacy benefit manager's network or other contractual agreement.
3	Sec. 1. 18 V.S.A. § 9471 is amended to read:
4	§ 9471. DEFINITIONS
5	As used in this subchapter:
6	* * *
7	(6) "Maximum allowable cost" means the per unit drug product
8	reimbursement amount, excluding dispensing fees, for a group of
9	therapeutically and pharmaceutically equivalent multisource generic drugs.
10	Sec. 2. 18 V.S.A. § 9473 is amended to read:
11	§ 9473. PHARMACY BENEFIT MANAGERS; REQUIRED
12	PRACTICES WITH RESPECT TO PHARMACIES
13	* * *
14	(c) For each drug for which a pharmacy benefit manager establishes a
15	maximum allowable cost in order to determine the reimbursement rate, the
16	pharmacy benefit manager shall do all of the following:
17	(1) make available, in a format that is readily accessible and
18	understandable by a pharmacist, a list of the drugs subject to maximum
19	allowable cost, the actual maximum allowable cost for each drug, and the
20	source used to determine the maximum allowable cost;

1	(2) update the maximum allowable cost list at least once every seven
2	calendar days; and
3	(3) establish or maintain a reasonable process for an administrative
4	appeals procedure process to allow a dispensing pharmacy provider to contest
5	a listed maximum allowable cost.
6	* * * Notice of Hospital Observation Status * * *
7	Sec. 3. 18 V.S.A. § 1905 is amended to read:
8	§ 1905. LICENSE REQUIREMENTS
9	Upon receipt of an application for license and the license fee, the licensing
10	agency shall issue a license when it determines that the applicant and hospital
11	facilities meet the following minimum standards:
12	* * *
13	(22) All hospitals shall provide oral and written notice to each individual
14	that the hospital places in observation status as required by section 1911a of
15	this title.
16	Sec. 4. 18 V.S.A. § 1911a is added to read:
17	1911a. NOTICE OF HOSPITAL OBSERVATION STATUS
18	(a) Each hospital shall provide oral and written notice to each individual
19	that the hospital places in observation status as soon as possible but no later
20	than 24 hours following such placement, unless the individual is discharged or
21	leaves the hospital before the 24-hour period expires. The written notice shall

1	be a uniform form developed by the Department of Health for use in all
2	hospitals.
3	(b) Each oral and written notice shall include:
4	(1) a statement that the individual is under observation as an outpatient
5	and is not admitted to the hospital as an inpatient;
6	(2) a statement that observation status may affect the individual's
7	Medicare, Medicaid, or private insurance coverage for hospital services,
8	including medications and pharmaceutical supplies, and for rehabilitative or
9	skilled nursing services at a skilled nursing facility if needed upon discharge
10	from the hospital; and
11	(3) a statement that the individual may contact his or her health
12	insurance provider, the Office of the Health Care Advocate, or the Vermont
13	State Health Insurance Assistance Program to understand better the
14	implications of placement in observation status.
15	(c) Each written notice shall include the name and title of the hospital
16	representative who gave oral notice, the date and time oral notice was given,
17	and contact information for the Office of the Health Care Advocate and the
18	Vermont State Health Insurance Assistance Program.
19	(d) Oral and written notice shall be provided in a manner that is
20	understood understandable by the individual placed in observation status or
21	by his or her legal guardian or authorized representative.

1	(e) Each written notice shall be signed and dated by the individual placed
2	in observation status, or if applicable by his or her legal guardian or authorized
3	representative, to verify receipt and an understanding of the oral and written
4	notice.
5	* * * Prospective Payments for Home Health Services * * *
6	Sec. 4. FINDINGS
7	The General Assembly finds that:
8	(1) In Vermont, the State reimburses home health agencies over
9	\$34 million annually in Medicaid fee-for-service payments.
10	(2) In October 2000, the federal Centers for Medicare and Medicaid
11	Services adopted a prospective payment system for Medicare that pays
12	home health agencies a predetermined rate for each 60-day episode of
13	home health care regardless of the number of visits the patient receives
14	during that period.
15	(3) Medicare's prospective payment system provides home health
16	agencies with incentives to provide the appropriate level of care to achieve
17	positive outcomes for Medicare patients.
18	(4) Vermont Medicaid's fee-for-service model encourages more
19	services instead of more efficient services.

1	(5) Home health services reimbursed under the Vermont Medicaid
2	program are currently delivered in a manner that limits the services
3	<u>clients may receive.</u>
4	(6) Losses at Vermont's home health agencies are becoming
5	unsustainable because Medicaid reimbursement rates are far below the
6	cost of delivering services.
7	(7) A Medicaid prospective payment system model will support
8	Vermont's payment reform efforts by providing more flexible, integrated,
9	and improved services to clients, reducing administrative costs at home
10	health agencies, and containing costs while providing greater financial
11	predictability to home health agencies and to the State.
12	Sec. 5. 33 V.S.A. § 1901h is added to read:
13	§ 1901h. PROSPECTIVE PAYMENT; HOME HEALTH SERVICES
14	(a) On or before January 1, 2016 and upon approval from the Centers
15	for Medicare and Medicaid Services, the Agency of Human Services
16	Department of Vermont Health Access shall modify reimbursement
17	methodologies to home health agencies, as defined in section 1951 of this
18	title, in order to implement a prospective payments system for the medical
19	services paid for by the Department and to replace the fee-for-service
20	system for home health agencies that provide services under Medicaid,
21	including nursing, therapies, licensed nursing assistants, nutritionists, and

1	hospice care; that provide pediatric rehabilitation services, including
2	physical therapy, occupational therapy, and speech-language pathology;
3	and that provide services under the Choices for Care program payment
4	methodologies.
5	(b) The prospective payment system shall:
6	(1) pay home health agencies a predetermined rate for each 60-day
7	episode of home health care, which shall be adjusted annually for
8	inflation;
9	(2) be budget neutral;
10	(3) not adjust payments based on patient acuity;
11	(4) not limit the number of episodes of care;
12	(5) eliminate the need for prior authorization for pediatric
13	rehabilitation services;
14	(6) establish risk corridors of three percent, such that if a home
15	health agency's profits exceed three percent, the excess shall be paid to the
16	Agency of Human Services or placed in a flexible fund for new or
17	noncovered services, while if a home health agency's losses exceed three
18	percent, the Agency of Human Services shall pay the difference to the
19	home health agency; and

1	(7) require home health agencies to report data to the Agency of
2	Human Services to evaluate the prospective payment system payment
3	methodology, including:
4	(A) details of each episode, including identifying patient visits by
5	discipline and providing the name of the certifying physician, the date on
6	which care began, and the primary diagnosis;
7	(B) costs reflecting revenue from services rendered under the
8	prospective payment system, the home health agency's total expenses, and
9	gains and losses;
10	(C) information regarding health outcomes; and
11	(D) monitoring and reporting on acute care hospitalization,
12	emergency care, and nursing home admissions using existing internal and
13	external resources.
14	(c) As used in this section, "home health agency" means an entity that
15	has received a certificate of need from the State to provide home health
16	services and is certified to provide services pursuant to 42 U.S.C.
17	<u>§ 1395x(o).</u>
18	(b) The Department shall develop the payment methodology in
19	collaboration with representatives of home health agencies. If practicable,
20	the Department:

1	(1) shall align the methodology with Medicare to reduce the
2	administrative burden on the agencies; and
3	(2) may include a quality payment in the methodology.
4	* * * Consumer Access to Health Care Cost Information * * *
5	Sec. 6. 18 V.S.A. § 9410a is added to read:
6	§ 9410a. HEALTH CARE QUALITY AND PRICE COMPARISON
7	(a)(1) The Green Mountain Care Board shall establish a website
8	allowing health care consumers to compare the price of medical care in
9	Vermont by insurance plan and by service or procedure, including office
10	visits, emergency care, radiologic services, and preventive care such as
11	mammography and colonoscopy, as well as comparing the cost of
12	prescription drugs. The website shall also enable consumers to compare
13	quality across providers. The Board may develop and administer the
14	comparison website itself or through a contract with a third party.
15	(2) The website shall allow a consumer to compare price by selecting
16	a specific service or procedure, insurance plan, and geographic region of
17	the State. Based on the criteria specified, the website shall provide the
18	consumer with an estimate for each provider of the amount the consumer
19	would pay for the service or procedure, an estimate of the amount the
20	insurance would pay, and an estimate of the combined payments.

1	(3) For consumers without health insurance or who choose to
2	compare costs without selecting an insurance plan, the website shall
3	provide the average cost for the service or procedure in the specified
4	geographic region.
5	(b) Cost data for the comparison website shall be derived from the
6	unified health care database established in section 9410 of this title.
7	(c) The Department of Vermont Health Access shall ensure that the
8	website for the Vermont Health Benefit Exchange includes a prominently
9	placed link to the comparison website established by this section to allow
10	health care consumers to make informed decisions about the health care
11	services they receive.
12	Sec. 7. 18 V.S.A. § 4634 is amended to read:
13	§ 4634. PRESCRIPTION DRUG PRICE DISCLOSURE
14	(a) Upon request, a pharmacy shall disclose to any consumer or health
15	care provider the usual and customary retail price of a prescription drug.
16	(b) With each prescription dispensed, a pharmacy shall disclose to the
17	consumer, in writing,.
18	(c) Each pharmacy the price of the prescription and any payment
19	toward the price required of the consumer shall display on or near the
20	pharmacy counter and on the pharmacy website, if any, the usual and
21	customary retail price of the 20 most commonly prescribed prescription

1	medications dispensed at that pharmacy, as well as the average price for
2	each of those prescription medications.
3	(d) For purposes of As used in this section:
4	(1) "Price of the prescription" means the amount charged by the
5	pharmacy to the consumer or, if applicable, to the consumer's health
6	benefit plan.
7	(2) "Usual and customary retail price" means the total price
8	charged to a consumer who does not have prescription drug coverage
9	under a health benefit plan.
10	(d)(e) In addition to any other remedy provided by law, the attorney
11	general Attorney General may file an action in superior court Superior
12	Court for a violation of this section. In any such action, the attorney
13	general Attorney General shall have the same authority to investigate and
14	to obtain remedies as if the action were brought under the Consumer
15	Protection Act, 9 V.S.A. chapter 63. Each violation of this section
16	constitutes a separate civil violation for which the attorney general
17	Attorney General may obtain relief.
18	* * * Oversight Committees * * *
19	Sec. 6. 2 V.S.A. chapter 24 is added to read:
20	CHAPTER 24. HEALTH CARE OVERSIGHT COMMITTEE
21	§ 851. CREATION OF COMMITTEE

I	(a) There is created a legislative Health Care Oversight Committee.
2	The Committee shall be appointed biennially and consist of ten members:
3	five members of the House appointed by the Speaker, not all from the
4	same political party, and five members of the Senate appointed by the
5	Senate Committee on Committees, not all from the same political party.
6	The House appointees shall include one member from the House
7	Committee on Human Services, one member from the House Committee
8	on Health Care, one member from the House Committee on
9	Appropriations, and two at-large members. The Senate appointees shall
10	include one member from the Senate Committee on Health and Welfare,
11	one member from the Senate Committee on Finance, one member from
12	the Senate Committee on Appropriations, and two at-large members.
13	(b) The Committee may adopt rules of procedure to carry out its
14	duties.
15	§ 852. FUNCTIONS AND DUTIES
16	(a) The Health Care Oversight Committee shall monitor, oversee, and
17	provide a continuing review of health care and human services programs
18	in Vermont when the General Assembly is not in session; provided,
19	however, that review of matters related to mental health and health care
20	reform shall remain in the jurisdiction of the Mental Health Oversight

1	and Health Reform Oversight Committees, respectively, for as long as
2	each Committee is authorized by law.
3	(b) In conducting its oversight and in order to fulfill its duties, the
4	Committee may consult with consumers, providers, advocates,
5	administrative agencies and departments, and other interested parties.
6	(c) The Committee shall work with, assist, and advise other committees
7	of the General Assembly, members of the Executive Branch, and the
8	public on matters relating to health care and human services programs.
9	(d) Annually, on or before January 15, the Committee shall report its
10	findings and any recommendations to the Governor and the committees of
11	jurisdiction.
12	§ 853. MEETINGS AND STAFF SUPPORT
13	(a) For attendance at meetings during adjournment of the General
14	Assembly, legislative members of the Committee shall be entitled to per
15	diem compensation and reimbursement of expenses pursuant to 2 V.S.A.
16	<u>§ 406.</u>
17	(b) The Office of Legislative Council and the Joint Fiscal Office shall
18	provide professional and administrative support to the Committee. The
19	Department of Financial Regulation, the Agency of Human Services, and
20	other agencies of the State shall provide information, assistance, and
21	support upon request of the Committee.

1	Sec. 7. MENTAL HEALTH OVERSIGHT COMMITTEE
2	(a) The Mental Health Oversight Committee is created to ensure that
3	consumers have access to a comprehensive and adequate continuum of
4	mental health services. The Committee shall be composed of one member
5	from each of the House Committees on Human Services, on Corrections
6	and Institutions, and on Appropriations and a member-at-large to be
7	appointed by the Speaker of the House, not all from the same party, and
8	one member from each of the Senate Committees on Health and Welfare,
9	on Institutions, and on Appropriations and one member-at-large to be
10	appointed by the Committee on Committees, not all from the same party.
11	Initial appointments shall be made upon passage of this act.
12	(b) Members of the Committee shall serve as the liaison to their
13	respective legislative standing committees with primary jurisdiction over
14	the various components of Vermont's mental health system. The
15	Committee shall work with, assist, and advise the other committees of the
16	General Assembly, members of the Executive Branch, and the public on
17	matters related to Vermont's mental health system.
18	(c) The Committee is authorized to meet up to six times per year while
19	the General Assembly is not in session to perform its functions under this
20	section.
21	(d) The Commissioner of Mental Health shall report to the Committee

1	as required by the Committee.
2	(e) For attendance at meetings during adjournment of the General
3	Assembly, legislative members of the Committee shall be entitled to per
4	diem compensation and reimbursement of expenses pursuant to 2 V.S.A.
5	<u>§ 406.</u>
6	(f) The Committee shall have the administrative, technical, and legal
7	assistance of the Office of Legislative Council and the Joint Fiscal Office.
8	(g) The Mental Health Oversight Committee shall provide a progress
9	report to each of the committees represented thereon on or before
10	<u>January 1, 2016.</u>
11	(h) The Committee shall cease to exist after January 1, 2016.
12	* * * Long-Term Care Evaluation Task Force * * *
13	Sec. 8. LONG-TERM CARE EVALUATION TASK FORCE
14	(a) Creation. There is created a Long-Term Care Evaluation Task
15	Force to assess and catalogue those in-home, long-term care programs that
16	are either operated by the State or subsidized by the State.
17	(b) Membership. The Task Force shall be composed of the following
18	10 members:
19	(1) the Chair of the Senate Committee on Health and Welfare or
20	designee, appointed by the Committee on Committees;

1	(2) the Chair of the House Committee on Human Services or
2	designee, appointed by the Speaker of the House;
3	(3) the Commissioner of Disabilities, Aging, and Independent Living
4	or designee;
5	(4) the Long-Term Care Ombudsman;
6	(5) a representative of elders, appointed by the Community of
7	Vermont Elders;
8	(6) a representative of retired persons, appointed by the American
9	Association of Retired Persons;
10	(7) a representative of the Area Agencies on Aging;
11	(8) a representative of home health care providers, appointed by the
12	Vermont Association of Home Health Agencies;
13	(9) a representative of the Support and Services at Home (SASH)
14	program; and
15	(10) a representative of private home health care providers,
16	appointed by Bayada Home Health Care.
17	(c) Powers and duties. The Task Force shall assess the availability and
18	effectiveness of in-home, long-term care services in Vermont that are
19	either State-operated or State-subsidized and create a catalogue of existing
20	services to determine where overlapping services or gaps in service may
21	exist.

1	(d) Assistance. The Task Force shall have the administrative,
2	technical, and legal assistance of the Department of Disabilities, Aging,
3	and Independent Living. For purposes of preparing any recommended
4	legislation, the Task Force shall have the assistance of the Office of
5	Legislative Council.
6	(e) Report. On or before January 15, 2016, the Task Force shall
7	submit a written report to the House Committee on Human Services and
8	to the Senate Committee on Health and Welfare with its findings and any
9	recommendations for rules or legislative action.
10	(f) Meetings.
11	(1) The Commissioner of Disabilities, Aging, and Independent
12	Living or designee shall call the first meeting of the Task Force to occur on
13	or before August 1, 2015.
14	(2) The Commissioner of Disabilities, Aging, and Independent
15	Living or designee shall serve as chair of the Task Force.
16	(3) A majority of the membership shall constitute a quorum.
17	(4) The Task Force shall cease to exist on February 1, 2016.
18	(g) Reimbursement.
19	(1) For attendance at meetings during adjournment of the General
20	Assembly, legislative members of the Task Force shall be entitled to per

1	diem compensation and reimbursement of expenses pursuant to 2 V.S.A.
2	§ 406 for no more than four meetings.
3	(2) Other members of the Task Force who are not employees of the
4	State of Vermont and who are not otherwise compensated or reimbursed
5	for their attendance shall be entitled to per diem compensation and
6	reimbursement of expenses pursuant to 32 V.S.A. § 1010 for no more than
7	four meetings.
8	* * * Reports * * *
9	Sec. 9. VERMONT HEALTH CARE INNOVATION PROJECT; UPDATES
10	The Project Director of the Vermont Health Care Innovation Project
11	(VHCIP) shall provide an update at least quarterly to the House Committees on
12	Health Care and on Ways and Means, the Senate Committees on Health and
13	Welfare and on Finance, and the Health Reform Oversight Committee
14	regarding VHCIP implementation and the use of the federal State Innovation
15	Model (SIM) grant funds. The Project Director's update shall include
16	information regarding:
17	(1) the VHCIP pilot projects and other initiatives undertaken using SIM
18	grant funds, including a description of the projects and initiatives, the timing of
19	their implementation, the results achieved, and the replicability of the results;
20	(2) how the VHCIP projects and initiatives fit with other payment and
21	delivery system reforms planned or implemented in Vermont;

1	(3) how the VHCIP projects and initiatives meet the goals of improving
2	health care access and quality and reducing costs;
3	(4) how the VHCIP projects and initiatives will reduce administrative
4	costs;
5	(5) how the VHCIP projects and initiatives compare to the principles
6	expressed in 2011 Acts and Resolves No. 48;
7	(6) what will happen to the VHCIP projects and initiatives when the
8	SIM grant funds are no longer available; and
9	(7) how to protect the State's interest in any health information
10	technology and security functions, processes, or other intellectual property
11	developed through the VHCIP.
12	Sec. 11. REDUCING PAPERWORK; WORKING GROUP
13	(a) The Green Mountain Care Board, in coordination with the Agency
14	of Human Services, shall convene a working group to evaluate the
15	information requirements of the quality and satisfaction surveys and
16	other forms required by:
17	(1) Medicare;
18	(2) Medicaid;
19	(3) rules adopted by the Department of Financial Regulation, the
20	Green Mountain Care Board, and the Agency of Human Services;
21	(4) the Blueprint for Health;

1	(5) designated agencies;
2	(6) accountable care organizations;
3	(7) the federal Screening, Brief Intervention, and Referral to
4	Treatment (SBIRT) grant;
5	(8) the National Committee for Quality Assurance (NCQA);
6	(9) 2000 Acts and Resolves No. 129;
7	(10) adverse childhood experience surveys; and
8	(11) other programs and initiatives.
9	(b) The working group shall recommend strategies for aligning survey
10	questions and other required forms across programs and initiatives in
11	order to reduce the administrative burden on health care providers in
12	completing all of the required surveys and forms. It shall also establish a
13	process to ensure that future surveys and forms are aligned across
14	programs and initiatives, to the extent that doing so is within the State's
15	control.
16	(c) On or before December 1, 2015, the working group shall report its
17	recommendations to the House Committee on Health Care, the Senate
18	Committees on Health and Welfare and on Finance, and the Health
19	Reform Oversight Committee.
20	Sec. 10. REDUCING DUPLICATION OF SERVICES; REPORT

1	(a) The Agency of Human Services shall evaluate the services offered by
2	each entity licensed, administered, or funded by the State, including the
3	designated agencies, to provide services to individuals receiving home- and
4	community-based long-term care services or who have developmental
5	disabilities, mental health needs, or substance use disorder. The Agency shall
6	determine areas in which there are gaps in services and areas in which
7	programs or services are inconsistent with the Health Resource Allocation
8	Plan or are overlapping, duplicative, or otherwise not delivered in the most
9	efficient, and cost-effective, and high-quality manner and shall develop
10	recommendations for consolidation or other modification to maximize
11	high-quality services, efficiency, service integration, and appropriate use of
12	public funds.
13	(b) On or before January 15, 2016, the Agency shall report its findings and
14	recommendations to the House Committee on Human Services and the Senate
15	Committee on Health and Welfare.
16	* * * Chemicals of Concern to Children * * *
17	Sec. 11. 18 V.S.A. § 1774(d) is amended to read:
18	(d) Commissioner of Health recommendation; assistance.
19	(1) Beginning on July 1, 2017, and biennially thereafter, the
20	Commissioner of Health shall recommend at least two chemicals of high
21	concern to children in children's products for review by the Working

1	Group. The Commissioner's recommendations shall be based on the
2	degree of human health risks, exposure pathways, and impact on sensitive
3	populations presented by a chemical of high concern to children.
4	(2) The Working Group shall have the administrative, technical,
5	and legal assistance of the Department of Health and the Agency of
6	Natural Resources.
7	Sec. 12. 18 V.S.A. § 1776 is amended to read:
8	§ 1776. RULEMAKING; ADDITIONAL CHEMICALS OF CONCERN
9	TO CHILDREN; PROHIBITION OF SALE
10	(a) Rulemaking authority. The Commissioner shall, after consultation
11	with the Secretary of Natural Resources, adopt rules as necessary for the
12	purposes of implementing, administering, or enforcing the requirements
13	of this chapter.
14	(b) Additional chemicals of concern to children. The Commissioner
15	may by rule add additional chemicals to the list of chemicals of high
16	concern to children, provided that the Commissioner of Health, on the
17	basis of the weight of credible, scientific evidence, has determined that a
18	chemical proposed for addition to the list meets both of the following
19	criteria in subdivisions (1) and (2) of this subsection:

1	(1) The Commissioner of Health has determined that an
2	authoritative governmental entity or accredited research university has
3	demonstrated that the chemical:
4	(A) harms the normal development of a fetus or child or causes
5	other developmental toxicity;
6	(B) causes cancer, genetic damage, or reproductive harm;
7	(C) disrupts the endocrine system;
8	(D) damages the nervous system, immune system, or organs or
9	causes other systemic toxicity; or
10	(E) is a persistent bioaccumulative toxic.
11	(2) The chemical has been found through:
12	(A) biomonitoring to be present in human blood, umbilical cord
13	blood, breast milk, urine, or other bodily tissues or fluids;
14	(B) sampling and analysis to be present in household dust, indoor
15	air, drinking water, or elsewhere in the home environment; or
16	(C) monitoring to be present in fish, wildlife, or the natural
17	environment.
18	(c) Removal of chemical from list. The Commissioner may by rule
19	remove a chemical from the list of chemicals of high concern to children
20	established under section 1773 of this title or rules adopted under this

1	section if the Commissioner determines that the chemical no longer meets
2	both of the criteria of subdivisions $(b)(1)$ and (2) of this section.
3	(d) Rule to regulate sale or distribution.
4	(1) The Commissioner, upon the recommendation of after
5	consultation with the Chemicals of High Concern to Children Working
6	Group, may adopt a rule to regulate the sale or distribution of a children's
7	product containing a chemical of high concern to children upon a
8	determination that:
9	(A) children will be exposed to a chemical of high concern to
10	children in the children's product there is potential for exposure of
11	children to the chemical of high concern; and
12	(B) there is a probability that, due to the degree of exposure or
13	frequency of exposure of a child to a chemical of high concern to children
14	in a children's product, exposure could cause or contribute to one or more
15	of the adverse health impacts listed under subdivision (b)(1) of this section
16	one or more safer alternatives to the chemical of high concern to children
17	are available.
18	(2) In determining whether children will be exposed to a chemical of
19	high concern in a children's product, the Commissioner shall review
20	available, credible information regarding:
21	(A) the market presence of the children's product in the State; or

1	(B) the type or occurrence of exposures to the relevant chemical
2	of high concern to children in the children's product;
3	(C) the household and workplace presence of the children's
4	product; or
5	(D) the potential and frequency of exposure of children to the
6	chemical of high concern to children in the children's product the
7	amounts of the chemical of high concern contained in the children's
8	product as reported under section 1775 of this title.
9	* * *
10	* * * Appropriation * * *
11	Sec. 13. APPROPRIATION
12	The sum of \$1,250,000.00 in Global Commitment funds is appropriated
13	from the General Fund to the Department of Vermont Health Access in
14	fiscal year 2016 to increase Medicaid reimbursement rates for home
15	health agencies and for implementation of the prospective payment
16	methodologies set forth in Sec. 5 of this act.
17	* * * Effective Dates * * *
18	Sec. 14. EFFECTIVE DATES
19	(a) Secs. 1 and 2 (pharmacy benefit managers), 9 and 10 (reports), and this
20	section shall take effect on passage.

on July 1, 2015.

1	(b) Secs. 3 and 4 (notice of hospital observation status), 5 (prospective
2	payments for home health services), 6 and 7 (reinstating oversight
3	committees), 8 (Long-Term Care Evaluation Task Force), 11 and 12
4	(chemicals of concern to children), and 13 (appropriation) shall take effect
5	on July 1, 2015.